mucosal membrane dryness
Products that synergistically combine plasma or plasma derivatives with chitosan offer a promising approach to the treatment of mucosal membrane dryness, particularly in the areas of oral and vaginal dryness.
Plasma, especially when it’s concentrated as in platelet-rich plasma (PRP), is rich in growth factors and proteins. These components are known to promote cell proliferation, tissue regeneration, and repair, making them beneficial for mucosal health. Additionally, the inherent composition of plasma naturally hydrates dry mucosal membranes.
Our chitosan ingredient is recognized for its strong mucoadhesive properties. When applied to mucosal surfaces, it may prolong contact time of therapeutic agents like those from plasma. Furthermore, chitosan may enable a controlled and sustained release, optimizing the benefits of incorporated agents, such as plasma-derived proteins.
When combined, these two components may offer enhanced benefits. The tissue-repairing benefits of plasma-derived products, combined with the sustained action of chitosan, potentially provide both relief and long-lasting therapeutic action.
Beyond just the delivery mechanism, the combination may also creates a barrier. Chitosan, when combined with plasma-derived products, may form a protective barrier on the mucosa, which should provides hydration and continually supplies the mucosa with growth factors and proteins.
We are evaluating disease and region specific applications. In the case of mouth dryness, a gel or spray containing both plasma derivatives and chitosan could provide relief from the discomfort of dryness, promote the healing of mucosal lesions, and may offer sustained hydration. For vaginal dryness, gels or suppositories that incorporate both these components may effectively be impactful.
learn more about:
our products
Our therapeutic formulations is suitable for a variety of products, including liquid eye drops, gels, ointments, contact lenses, contoured bandages, and wound dressings. We believe this formulation will promote healing of epithelial (surface cell) disorders, such as dry eye disease, ophthalmic burns, and chronic wounds.
our platform
Our platform leverages plasma from donated human blood and a proprietary antimicrobial molecule (form of chitosan). The tissue-repairing benefits of plasma-derived products, combined with the sustained action of chitosan, may provide relief and long-lasting therapeutic action.
our platform
